I-nephrogenic systemic fibrosis yisifo esingavamile esihlala kakhulu kubantu abanesifo sokwehluleka kwesibindi esikhulile, kungakhathaliseki ukuthi banokwelashwa nge-dialysis noma cha. I-nephrogenic systemic fibrosis ingafana nezifo zesikhumba, njenge-scleroderma ne-scleromyxedema, lapho ukuqina nokukhanya kuvela ezindaweni ezinkulu zesikhumba.
I-nephrogenic systemic fibrosis ingathinta namanye amalungu omzimba, njengentliziyo nemiphunga, futhi ingabangela ukufinyeka okukhubaza imisipha nemisipha yemisipha ezinhlangothini (ukuncika kwamajozi).
Kubantu abanye abanesifo sesibindi esikhulile, ukubonisana nezikhali ze-gadolinium-based contrast agents (iqembu 1) ngesikhathi sokwenza i-magnetic resonance imaging (MRI) nezinye izifundo zokwenza izithombe kuye kwabonakala njengokuthinta ukuthuthukiswa kwalesi sifo. Ukuqaphela lobu buhlobo kuye kwancishisa kakhulu inani le-nephrogenic systemic fibrosis. Izidakamizwa ezintsha ze-gadolinium-based contrast agents (iqembu 2) azihambisani nokungena engozini enkulu ye-nephrogenic systemic fibrosis.
I-nephrogenic systemic fibrosis ingaqala ezinsukwini ezimbalwa kuya ezinyangeni, ngisho naseminyakeni, ngemva kokubekwa ekuxhumaneni nomkhiqizo wokuhlola osekhulile obunomkhiqizo we-gadolinium (iqembu 1). Amanye ama-sign nama-symptoms e-nephrogenic systemic fibrosis angafaka:
Kwabanye abantu, ukuhileleka kwemisipha nezingxenye zomzimba kungabangela:
Isimo ngokuvamile sihlala isikhathi eside (esingapheli), kodwa abanye abantu bangase bathuthuke. Kubantu abambalwa, kungabangela ukukhubazeka okukhulu, ngisho nokufa.
Imbangela eqondile ye-nephrogenic systemic fibrosis ayiqondakali ngokuphelele. I-fibrous connective tissue yakha oluswini nakwi-connective tissues, okuholela ekwenzakaleni kwezicubu emzimbeni wonke, ikakhulu oluswini nakwi-subcutaneous tissues.
Ukubonisana ne-gadolinium-based contrast agents endala (iqembu 1) ngesikhathi se-magnetic resonance imaging (MRI) kuye kwabonakala njengokuthinta ukuthuthukiswa kwalesi sifo kubantu abanesifo sezinso. Lo mongo wokwanda kuthiwa uxhumekile ekubeni izinso zinekhono eliphansi lokususa i-contrast agent egazini.
I-Food and Drug Administration (FDA) iphakamisa ukugwema i-gadolinium-based contrast agents endala (iqembu 1) kubantu abanesifo sezinso esibuhlungu noma i-chronic kidney disease.
Ezinye izimo zingandisa ingozi ye-nephrogenic systemic fibrosis uma zidibene nesifo sezinso esikhoyo nokubonisana ne-gadolinium-based contrast agents endala (iqembu 1), kodwa uxhumano alucaci. Lezi zihlanganisa:
Ingozi enkulu kunazo zonke ye-nephrogenic systemic fibrosis ngemva kokubekwa ezingozini ze-gadolinium-based contrast agents (iqembu 1) kwenzeka kubantu abalandelayo:
Ukugwema ukusetshenziswa kwezinto ezikhuthazayo ezikhuluma i-gadolinium ezindala (iqembu 1) kubalulekile ekuvinjeni i-nephrogenic systemic fibrosis, njengoba izinto ezikhuthazayo ezikhuluma i-gadolinium ezintsha (iqembu 2) ziphephile futhi azixhunyaniswanga nenkinga eyenzeka ngokwanda.
Ukuxilongwa kwe-nephrogenic systemic fibrosis kwenziwa ngokusebenzisa:
Asikho ukwelashwa kwe-nephrogenic systemic fibrosis, futhi asikho ukwelashwa okuphumelelayo ngokuqhubekayo ekuqedeni noma ekuphenduleni intuthuko yesifo. I-Nephrogenic systemic fibrosis ivele kancane, okwenza kube nzima ukuqhuba izifundo ezinkulu.
Ezinye izindlela zokwelapha zibonise impumelelo encane kubantu abane-nephrogenic systemic fibrosis, kodwa ucwaningo olwengeziwe luyadingeka ukuze kutholakale ukuthi lezi zindlela zokwelapha ziyasiza yini:
Le miyekezo iyocwaningo, kodwa ayisetshenziswanga njengamanje. Ibonise ukuthi iyabasiza abanye abantu, kodwa imiphumela emibi iyancipha ukusetshenziswa kwayo:
Umshwana wokuzihlangula: I-August iyinkundla yolwazi lwezempilo futhi izimpendulo zayo azihlanganisi iseluleko sezokwelapha. Njalo thintana nochwepheshe bezokwelapha onelayisensi eduze nawe ngaphambi kokwenza noma yiluphi ushintsho.